Comments on: Liver-Limited Colon Cancer http://fightcolorectalcancer.org/dr_lenz/2009/10/liver-limited_colon_cancer We envision victory over colorectal cancer Thu, 09 Feb 2012 15:03:01 +0000 hourly 1 http://wordpress.org/?v=3.3.1 By: Anon http://fightcolorectalcancer.org/dr_lenz/2009/10/liver-limited_colon_cancer/comment-page-1#comment-2367 Anon Fri, 06 Nov 2009 06:27:50 +0000 http://fightcolorectalcancer.org/?p=6354#comment-2367 If the patient has stage 3b adenocarcinoma of the colon, post hemicolectomy, with 4 out of 28 lymphnodes resected, and wild type of KRAS mutation, then would it be beneficial to add Cetuximab to the regime of capacetabine and oxaliplatine? If the patient has stage 3b adenocarcinoma of the colon, post hemicolectomy, with 4 out of 28 lymphnodes resected, and wild type of KRAS mutation, then would it be beneficial to add Cetuximab to the regime of capacetabine and oxaliplatine?

]]> By: Heinz-Josef Lenzq http://fightcolorectalcancer.org/dr_lenz/2009/10/liver-limited_colon_cancer/comment-page-1#comment-2344 Heinz-Josef Lenzq Thu, 29 Oct 2009 14:31:27 +0000 http://fightcolorectalcancer.org/?p=6354#comment-2344 very good question. we dont know N0147 the adjuvant trial for colon cancer is still ongoing but will help us to understand the role of erbitux in the adjuvant......but convinced that resection of metastatic disease is not the same adjuvant therapy as resected of primary tumor since in the first case tumors metastatsized and are more aggressive. very good question. we dont know N0147 the adjuvant trial for colon cancer is still ongoing but will help us to understand the role of erbitux in the adjuvant……but convinced that resection of metastatic disease is not the same adjuvant therapy as resected of primary tumor since in the first case tumors metastatsized and are more aggressive.

]]> By: Banma http://fightcolorectalcancer.org/dr_lenz/2009/10/liver-limited_colon_cancer/comment-page-1#comment-2343 Banma Thu, 29 Oct 2009 11:50:15 +0000 http://fightcolorectalcancer.org/?p=6354#comment-2343 Let's say a patient has metastatic colon cancer limited to the liver. The tumor is wild-type KRAS, the patient has neoadjuvant chemotherapy (say Folfox) with an EGFR inhibitor (say cetuximab) and responds very well. The liver is then successfully resected and the patient has the same adjuvant chemo. Does this scenario suggest anything about the likelihood of recurrence? You mention that the EGFR pathway is important in the tumor environment of the liver; is it also important in microscopic disease? Let’s say a patient has metastatic colon cancer limited to the liver. The tumor is wild-type KRAS, the patient has neoadjuvant chemotherapy (say Folfox) with an EGFR inhibitor (say cetuximab) and responds very well. The liver is then successfully resected and the patient has the same adjuvant chemo.

Does this scenario suggest anything about the likelihood of recurrence? You mention that the EGFR pathway is important in the tumor environment of the liver; is it also important in microscopic disease?

]]>